okt10-b10
mAbexperimentalADC
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2022 (NCT04466475)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Payload
- astatine 211
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04579523 | Phase 1 | Feb 1, 2022 | National Cancer Institute (NCI), University of Washington |
| NCT04466475 | Phase 1 | Jan 31, 2022 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2022 |
| University of Washington | Academic/Hospital | 2 | 2 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1